» Articles » PMID: 17967430

NF-kappa B-mediated Adaptive Resistance to Ionizing Radiation

Overview
Date 2007 Oct 31
PMID 17967430
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Ionizing radiation (IR) began to be a powerful medical modality soon after Wilhelm Röntgen's discovery of X-rays in 1895. Today, more than 50% of cancer patients receive radiotherapy at some time during the course of their disease. Recent technical developments have significantly increased the precision of dose delivery to the target tumor, making radiotherapy more efficient in cancer treatment. However, tumor cells have been shown to acquire a radioresistance that has been linked to increased recurrence and failure in many patients. The exact mechanisms by which tumor cells develop an adaptive resistance to therapeutic fractional irradiation are unknown, although low-dose IR has been well defined for radioadaptive protection of normal cells. This review will address the radioadaptive response, emphasizing recent studies of molecular-level reactions. A prosurvival signaling network initiated by the transcription factor NF-kappa B, DNA-damage sensor ATM, oncoprotein HER-2, cell cyclin elements (cyclin B1), and mitochondrial functions in radioadaptive resistance is discussed. Further elucidation of the key elements in this prosurvival network may generate novel targets for resensitizing the radioresistant tumor cells.

Citing Articles

Peptide hydrogel-drug conjugates for tailored disease treatment.

Cauwenbergh T, Ballet S, Martin C Mater Today Bio. 2025; 31:101423.

PMID: 39944533 PMC: 11815290. DOI: 10.1016/j.mtbio.2024.101423.


Effect of Selenium and Selenoproteins on Radiation Resistance.

Zhang S, Zhang G, Wang P, Wang L, Fang B, Huang J Nutrients. 2024; 16(17).

PMID: 39275218 PMC: 11396913. DOI: 10.3390/nu16172902.


Concise review: breast cancer stems cells and their role in metastases.

Farahani M, Farjadmehr M, Atashi A, Momeni A, Behzadifard M Ann Med Surg (Lond). 2024; 86(9):5266-5275.

PMID: 39238997 PMC: 11374310. DOI: 10.1097/MS9.0000000000002270.


Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway.

Yang W, Wei M, Lee Y, Huang C, Kuo S Transl Oncol. 2024; 49:102092.

PMID: 39153367 PMC: 11381799. DOI: 10.1016/j.tranon.2024.102092.


: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.

Medeiros M, Guenka S, Bastos D, Oliveira K, Brassesco M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931401 PMC: 11206879. DOI: 10.3390/ph17060734.


References
1.
Al-Hajj M, Becker M, Wicha M, Weissman I, Clarke M . Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004; 14(1):43-7. DOI: 10.1016/j.gde.2003.11.007. View

2.
Datta R, Taneja N, Sukhatme V, Qureshi S, Weichselbaum R, Kufe D . Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A. 1993; 90(6):2419-22. PMC: 46098. DOI: 10.1073/pnas.90.6.2419. View

3.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

4.
Jung M, Dritschilo A . NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol. 2001; 11(4):346-51. DOI: 10.1053/srao.2001.26034. View

5.
Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S . Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res. 2000; 254(1):14-24. DOI: 10.1006/excr.1999.4733. View